TA-993 maleate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526979

CAS#: 150591-06-3

Description: TA-993 is a calcium channel antagonist potentially for the treatment of chronic peripheral arterial occlusive. TA-993 has a comparable antithrombotic effect with other antiplatelet agents, and thus it is a possible remedy for thrombotic and embolic diseases. TA-993 may become a clinically useful antiplatelet agent of this structure series.

Price and Availability




TA993 maleate is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 526979
Name: TA-993 maleate
CAS#: 150591-06-3
Chemical Formula: C27H32N2O7S
Exact Mass:
Molecular Weight: 528.62
Elemental Analysis: C, 61.35; H, 6.10; N, 5.30; O, 21.19; S, 6.06

Related CAS #: 150591-06-3 (maleate)   122024-96-8 (free)  

Synonym: TA993 maleate, TA993, TA-993, TA 993

IUPAC/Chemical Name: 5-(2-(dimethylamino)ethyl)-8-methyl-4-oxo-2-(p-tolyl)-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate maleate


InChi Code: InChI=1S/C23H28N2O3S.C4H4O4/c1-15-6-9-18(10-7-15)22-21(28-17(3)26)23(27)25(13-12-24(4)5)19-11-8-16(2)14-20(19)29-22;5-3(6)1-2-4(7)8/h6-11,14,21-22H,12-13H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1-


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Katoh M, Karasawa T, Doi H, Odawara A. Effects of the antiplatelet agent TA-993 and its metabolite MB3 on the hemorheological properties of rat and human erythrocytes. Thromb Res. 2001 Oct 15;104(2):105-12. PubMed PMID: 11672754.

2: Katoh M, Karasawa T, Watanabe A, Takagi M, Ikeo T, Odawara A. Inhibitory effects of TA-993 and its metabolite MB3 on platelet activation induced by collagen and U-46619 in human platelets. Biol Pharm Bull. 2001 May;24(5):501-4. PubMed PMID: 11379769.

3: Doi H, Kaburaki M, Inoue H, Suzumura K, Narita H. Protective effect of TA-993, a novel therapeutic agent for peripheral circulatory insufficiency, on skeletal muscle fatigue in a rat model of hindlimb ischemia. Jpn J Pharmacol. 2000 May;83(1):73-81. PubMed PMID: 10887943.

4: Katoh M, Karasawa T, Doi H, Odawara A, Takagi M, Ikeo T, Narita H. Antiplatelet mechanisms of TA-993 and its metabolite MB3 in ADP-induced platelet aggregation. Eur J Pharmacol. 2000 Jul 7;399(2-3):91-6. PubMed PMID: 10884507.

5: Kaburaki M, Yabana H, Doi H, Nagata K, Narita H, Murata S. The mechanism of the increasing action of TA-993, a new 1,5- benzothiazepine derivative, on limb blood flow in anesthetized dogs: selective suppression of sympathetic nerve activity. J Pharmacol Exp Ther. 1999 Mar;288(3):1167-73. PubMed PMID: 10027855.

6: Kaburaki M, Doi H, Narita H, Odawara A, Yasoshima A, Murata S. Antithrombotic action of TA-993, a new 1,5-benzothiazepine derivative, in a canine model of femoral arterial thrombosis. J Cardiovasc Pharmacol. 1998 Mar;31(3):470-7. PubMed PMID: 9514194.

7: Kaburaki M, Inoue H, Doi H, Yasuhara M, Narita H. Cardiovascular effects of 1,5-benzothiazepine derivatives having a l-cis and d-cis configuration in anesthetized dogs. Biol Pharm Bull. 1998 Jan;21(1):50-5. PubMed PMID: 9477168.

8: Kaburaki M, Narita H, Yabana H, Karasawa T, Doi H, Murata S. Cardiovascular effect of a new 1,5-benzothiazepine derivative TA-993 in anesthetized dogs. J Cardiovasc Pharmacol. 1998 Feb;31(2):240-7. PubMed PMID: 9475265.

9: Odawara A, Kikkawa K, Katoh M, Toryu H, Shimazaki T, Sasaki Y. Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation. Circ Res. 1996 Apr;78(4):643-9. PubMed PMID: 8635222.

10: Narita H, Kaburaki M, Doi H, Yasoshima A, Murata S. Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. Jpn J Pharmacol. 1995 Aug;68(4):397-404. PubMed PMID: 8531414.